JP7699539B2 - 多量体タンパク質の形成を阻害するバインダー - Google Patents

多量体タンパク質の形成を阻害するバインダー Download PDF

Info

Publication number
JP7699539B2
JP7699539B2 JP2021518942A JP2021518942A JP7699539B2 JP 7699539 B2 JP7699539 B2 JP 7699539B2 JP 2021518942 A JP2021518942 A JP 2021518942A JP 2021518942 A JP2021518942 A JP 2021518942A JP 7699539 B2 JP7699539 B2 JP 7699539B2
Authority
JP
Japan
Prior art keywords
protein
polypeptide
variant
tnf
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021518942A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022501063A (ja
JP2022501063A5 (cg-RX-API-DMAC7.html
Inventor
オリビエ キッテン
マシュー シニエ
シモン ユエ
アンヌ シュヴレル
Original Assignee
アフィロジック
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アフィロジック filed Critical アフィロジック
Publication of JP2022501063A publication Critical patent/JP2022501063A/ja
Publication of JP2022501063A5 publication Critical patent/JP2022501063A5/ja
Priority to JP2025064215A priority Critical patent/JP2025108528A/ja
Application granted granted Critical
Publication of JP7699539B2 publication Critical patent/JP7699539B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1086—Preparation or screening of expression libraries, e.g. reporter assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2021518942A 2018-10-07 2019-10-06 多量体タンパク質の形成を阻害するバインダー Active JP7699539B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025064215A JP2025108528A (ja) 2018-10-07 2025-04-09 多量体タンパク質の形成を阻害するバインダー

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306324.7A EP3632924A1 (en) 2018-10-07 2018-10-07 Binders for inhibiting formation of multimeric proteins
EP18306324.7 2018-10-07
PCT/EP2019/076986 WO2020074402A1 (en) 2018-10-07 2019-10-06 Binders for inhibiting formation of multimeric proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025064215A Division JP2025108528A (ja) 2018-10-07 2025-04-09 多量体タンパク質の形成を阻害するバインダー

Publications (3)

Publication Number Publication Date
JP2022501063A JP2022501063A (ja) 2022-01-06
JP2022501063A5 JP2022501063A5 (cg-RX-API-DMAC7.html) 2022-10-07
JP7699539B2 true JP7699539B2 (ja) 2025-06-27

Family

ID=64017330

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021518942A Active JP7699539B2 (ja) 2018-10-07 2019-10-06 多量体タンパク質の形成を阻害するバインダー
JP2025064215A Pending JP2025108528A (ja) 2018-10-07 2025-04-09 多量体タンパク質の形成を阻害するバインダー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025064215A Pending JP2025108528A (ja) 2018-10-07 2025-04-09 多量体タンパク質の形成を阻害するバインダー

Country Status (5)

Country Link
US (1) US20210380647A1 (cg-RX-API-DMAC7.html)
EP (2) EP3632924A1 (cg-RX-API-DMAC7.html)
JP (2) JP7699539B2 (cg-RX-API-DMAC7.html)
ES (1) ES3068042T3 (cg-RX-API-DMAC7.html)
WO (1) WO2020074402A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3004650B1 (fr) * 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
EP4043481A1 (en) 2021-02-15 2022-08-17 Affilogic Compounds and methods for extending half life of biomolecules
EP4190358A1 (en) 2021-12-05 2023-06-07 Affilogic Polypeptide as carrier for intestinal barrier crossing

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511691A (ja) 2006-12-04 2010-04-15 インスティティ・パスツール 新たな特異的結合体を工学的に操作するための足場として使用されるob−フォールド
WO2017161096A1 (en) 2016-03-16 2017-09-21 Tarveda Therapeutics, Inc. Antibody mimic conjugates and particles

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007011891A2 (en) * 2005-07-15 2007-01-25 Strategene California Dna binding protein-polymerase chimeras
ZA200810836B (en) 2006-05-26 2010-07-28 Obodies Ltd OB fold domains
FR2974816A1 (fr) 2011-05-04 2012-11-09 Centre Nat Rech Scient Methode de generation de proteines
FR3004650B1 (fr) 2013-04-22 2015-05-29 Affilogic Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
FR3027521B1 (fr) 2014-10-24 2016-12-16 Affilogic Compositions pour administration par voie orale
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010511691A (ja) 2006-12-04 2010-04-15 インスティティ・パスツール 新たな特異的結合体を工学的に操作するための足場として使用されるob−フォールド
WO2017161096A1 (en) 2016-03-16 2017-09-21 Tarveda Therapeutics, Inc. Antibody mimic conjugates and particles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biotechnology and Bioengineering,Vol.114, No.3,pp.481-491
PLoS ONE,2010年,Vol.5, No.5, e10728,pp.1-10

Also Published As

Publication number Publication date
JP2022501063A (ja) 2022-01-06
JP2025108528A (ja) 2025-07-23
EP3861011B1 (en) 2026-02-11
WO2020074402A1 (en) 2020-04-16
EP3861011A1 (en) 2021-08-11
ES3068042T3 (es) 2026-05-27
EP3861011C0 (en) 2026-02-11
US20210380647A1 (en) 2021-12-09
EP3632924A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
JP2025108528A (ja) 多量体タンパク質の形成を阻害するバインダー
AU2007330409B2 (en) OB-fold used as scaffold for engineering new specific binders
Ubah et al. Novel, anti-hTNF-α variable new antigen receptor formats with enhanced neutralizing potency and multifunctionality, generated for therapeutic development
JP2019501885A (ja) 多特異性抗体
KR101740030B1 (ko) ScFv 항체 라이브러리, 이의 제조방법 및 이를 이용한 ScFv 항체 스크리닝 방법
JP2019501887A (ja) 多特異性抗体
Wang et al. Construction of a single chain variable fragment antibody (scFv) against tetrodotoxin (TTX) and its interaction with TTX
Angelini et al. Directed evolution of broadly crossreactive chemokine-blocking antibodies efficacious in arthritis
CN114380906B (zh) 一种抗il-17a的单域抗体及其用途
Sun et al. Improvement in affinity and thermostability of a fully human antibody against interleukin-17A by yeast-display technology and CDR grafting
US20230120167A1 (en) Variants of sac7d and their use in cancer therapy
US20240124531A1 (en) Compounds and methods for extending half life of biomolecules
CN114555633A (zh) 用于靶向扩增免疫效应细胞的方法和材料
CN116829584A (zh) 一种抗pd-1的单域抗体
KR101482237B1 (ko) 항 il-6r 및 tnfr2을 포함하는 이중특이적 단백질을 발현하는 미니서클 벡터를 포함하는 자가 면역 질환 치료용 약학 조성물
CN111909268B (zh) 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
EP4059949A1 (en) Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders
Dong et al. The Protective Antibodies Induced by a Novel Epitope of Human TNF-α Could Suppress the Development of Collagen-Induced Arthritis
US20260116924A1 (en) Polypeptide as carrier for intestinal barrier crossing
Xu et al. Surrobodies with functional tails
Geng et al. Screening and Characterization of EGFR-Targeted Specific Nanobodies
CN117597353A (zh) 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途
HK1117548B (en) Ob-fold used as scaffold for engineering new specific binders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231017

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240318

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250617

R150 Certificate of patent or registration of utility model

Ref document number: 7699539

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150